New global trials help to make FOSRENOL(R) the most extensively studied modern phosphate binder

The new studies which will focus on reaching target serum phosphate levels as defined by the K/DOQI guidelines (Kidney Disease Outcomes Quality initiative)1 will strengthen FOSRENOL's position as the most extensively studied modern phosphate binder.

The trials will build on earlier phase III studies with FOSRENOL, reviewed today at the ERA-EDTA2 Congress in Lisbon, which demonstrated that patients with end stage renal disease (ESRD) treated with FOSRENOL can largely avoid the damaging consequences of hyperphosphataemia (excessively high phosphate levels in the blood) seen in as many as 80% of dialysis patients3.

"Effective management of hyperphosphataemia is a crucial part of management for patients on dialysis", commented Professor Jorge Cannata-Andia, of the Hospital Central de Asturias, Oviedo, Spain. "This silent condition has dangerous consequences as it disrupts the delicate interplay between the body's levels of calcium, parathyroid hormone and vitamin D, resulting in calcium deposits in the vasculature, which contribute to cardiovascular disease, and renal bone disease, which may give rise to skeletal deformities, pain and fractures."

Paradoxically, use of calcium-based phosphate binders the current mainstay of treatment for hyperphosphataemia can exacerbate vascular calcification by increasing blood calcium levels beyond acceptable levels (hypercalcaemia). In addition, calcium-based phosphate binders are associated with long-term bone problems of their own 4,5. In contrast, a much lower incidence of hypercalcaemia has been seen with FOSRENOL 6,7, which lowers serum phosphate to target levels within eight weeks and maintains this long-term 6,8 without increasing blood calcium levels.

Moreover, extensive bone biopsy studies have shown that 59% of patients treated with FOSRENOL moved towards normalisation of pre-existing bone disease compared with 21% on c

Contact: Elizabeth Park
Resolute Communications

Page: 1 2

Related medicine news :

1. Envisat enables first global check of regional methane emissions
2. New thrust needed to tackle health inequalities globally says UCL scientist
3. A global treatment for iron deficiency
4. 4 million more health workers required to improve global health
5. IU Medical School poised to host global HIV/AIDS conference
6. Tony Blair launches UKs new global AIDS strategy
7. Countries need greater support and less stringent conditions if global fund goals are to be met
8. Chronic diseases need global health attention
9. ESC highlights need for screening and global risk management as statins move over the counter in UK
10. Urgent need for investment in human resources to respond to global health crises
11. First global approval for FOSRENOL (lanthanum carbonate)

Post Your Comments:

(Date:9/1/2020)... ... September 01, 2020 , ... Dr. Kiran Gill is a ... of the face, breast, and body. In 2018, she founded Aesthetics in Plastic ... and aesthetic practice in Southwest Florida. Dr. Gill and her team offer surgical ...
(Date:8/31/2020)... ... August 31, 2020 , ... Ocean Springs, Mississippi-based pharmaceutical distributor ... first responders across the United States. Since the start of the global COVID-19 ... medical centers , hospitals , firefighters , and public ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... to dental groups in the United States, today announced the grand opening of ... CA. , Patients will enjoy convenient hours, a comfortable office, and full-service ...
(Date:8/31/2020)... , ... August 31, 2020 , ... ... working, both directly with persons with autism and other developmental disabilities, as well ... early intervention, parent education, adolescents with autism, school consultation, and staff development. She ...
(Date:8/28/2020)... ... 28, 2020 , ... WHAT , Hespiro™ is a new ... conditions, including COVID-19, while reducing the need for scarce mechanical ventilators. It not ... and scrubs it free of carbon dioxide in a completely closed “rebreather” system, ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... ... September 03, 2020 , ... ... Lab ( https://www.colorado.edu/lab/vance/masks ), an aerosol and engineering lab, conducted tests on Q&J’s ... against the COVID-19 virus than many other masks. Q&J face masks have both ...
(Date:9/2/2020)... ... ... U.S. Dermatology Partners is excited to welcome Board-Certified Dermatologist and ... Bethesda Dermatopathology Lab. , Jonathan Lee, MD grew up in the California Bay ... on to receive his M.D. with Honors from Harvard Medical School and pre-doctoral surgical ...
(Date:9/1/2020)... ... ... Breast and ovarian cancers are common diseases that affect many women. ... 7,500 women per year) and 10% of ovarian cancers (about 2,000 women per year) ... detectable in the Women’s Excellence Genetic Testing Program. , Dr. Jonathan Zaidan, MD, FACOG, ...
Breaking Medicine Technology:
Cached News: